NCT05282420

Ranibizumab Versus Aflibercept for CRVO in Young Patients.

Ranibizumab Versus Aflibercept for Macular Edema Secondary to Non-ischemic Central Retinal Vein Occlusion in Young Adult Patients.

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: South Valley University · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

this study will compare the efficacy and safety of use either Ranibizumab and Aflibercept in treatment of macular edema resulting from non ischemic central retinal vein occlusion in patients younger than 5o years old

Detailed description

This is a prospective randomized interventional study, Forty eyes of forty patients younger than 50 years with macular edema due to non-ischemic CRVO were enrolled in the study. Patients will be randomized into 2 groups. First group will receive intravitreal injection of Ranibizumab 0.5 mg\\0.1ml. the second group will receive intravitreal injection of 2.0 mg\\0.1 ml Aflibercept. All patients will be followed up for 12 months.

Conditions

• Non-Ischemic Central Retinal Vein Occlusion With Macular Edema

Interventions

Type	Name	Description
PROCEDURE	intravitreal injection of Ranibizumab	intravitreal injection of Anti-VEGF Ranibizumab (Lucentis®; manufactured in the United States by Genentech/Roche)
PROCEDURE	intravitreal injection of Aflipercept	intravitreal injection of Anti-VEGF Aflibercept (Eylea®; manufactured in the United States)
DRUG	Ranibizumab	Ranibizumab
DRUG	Aflibercept	Aflipercept

Timeline

• Start date: 2021-02-01
• Primary completion: 2022-04-01
• Completion: 2022-05-31
• First posted: 2022-03-16
• Last updated: 2022-03-16

Locations

1 site across 1 country: Egypt

Regulatory

• FDA-regulated drug study